Background-Long-term clinical outcomes of everolimus-eluting stent (EES) compared with sirolimus-eluting stent (SES) have not been evaluated fully yet, especially whether EES implantation could positively affect late adverse events reported after SES implantation occurring >1 year. Methods and Results-In this all-comer prospective multicenter randomized open-label trial, 3196 patients were assigned randomly to implant either EES (n=1596) or SES (n=1600). At 3 years, EES was noninferior to SES on the primary safety end point (all-cause death or myocardial infarction; 10.1% versus 11.5%; noninferiority P <0.001; and superiority P=0.19). Cumulative incidence of definite stent thrombosis was low and was not significantly different between the 2 groups (0.5% versus 0.6%; P=0.81). There was no significant difference in the efficacy end point of target-lesion revascularization between the EES and SES groups (6.6% versus 7.9%; P=0.16). However, the cumulative incidence of target-lesion failure (cardiac death/target-vessel myocardial infarction/ischemia-driven target-lesion revascularization) was significantly lower in the EES group than in the SES group (8.8% versus 11.4%; P=0.01). By a landmark analysis at 1 year, the cumulative incidence of very late stent thrombosis and late target-lesion revascularization was not significantly different between the 2 groups (0.2% versus 0.2%; P=0.99 and 2.2% versus 2.9%; P=0.21, respectively). Conclusions-The efficacy and safety outcomes for this trial after EES implantation remained comparable with those after SES implantation through 3-year follow-up. However, improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the significantly lower cumulative incidences of target-lesion failure, which has been the most widely used primary end point in the stent-versus-stent trials. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035450.
M ultiple previous head-to-head randomized trials comparing everolimus-eluting stent (EES), a second-generation drug-eluting stents (DESs), with sirolimus-eluting stent (SES), which was the most widely used first-generation DES, have demonstrated comparable results with respect to the efficacy and safety outcomes ≤1 year. [1] [2] [3] Recent studies suggested a favorable outcome of EES compared with SES in terms of very late stent thrombosis (VLST) >1 year after stent implantation, which was considered to be one of the major concerns of the first-generation DES. [4] [5] [6] [7] However, these reports were based on either observational studies using historical control or on meta-analyses that incorporate indirect comparison or include limited data >1 year. Head-to-head randomized trials comparing EES with SES reporting clinical outcomes >1 year after implantation were currently limited. 2, 8, 9 The Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) is the largest prospective multicenter randomized trial comparing EES with SES. 1, 10 At 1 year, EES was demonstrated to be noninferior to SES for the primary efficacy end point of target-lesion revascularization (TLR) without any significant differences in the efficacy and safety outcomes. Longer term clinical follow-up, however, was clearly needed to evaluate whether EES could overcome the limitations of SES, such as late TLR and VLST >1 year after implantation. Therefore, we report 3-year clinical outcomes from the RESET study, focusing on late adverse events >1 year after implantation.
Methods

Study Design and Patients
As previously described in detail, the RESET study is a prospective multicenter randomized open-label trial comparing EES with SES in daily clinical practice in Japan. 1 Patients scheduled for percutaneous coronary intervention (PCI) using DES either electively or emergently among 100 participating centers (List A in the Data Supplement) were enrolled in the study without any exclusion criteria (all-comers design). The study complied with the provisions of the Declaration of Helsinki, and the study protocol was approved by the institutional review board at each participating center. Written informed consent was obtained from all the study subjects. The study was registered at the ClinicalTrials.gov (NCT01035450).
Patients scheduled for PCI were assigned randomly a coronary stent releasing either everolimus (Xience V) or sirolimus (Cypher Select-plus). Randomization was performed before stent implantation and was stratified by center, diabetic status, and participation in the imaging substudies (angiography, intravascular ultrasound, optical coherence tomography, and coronary endothelial function). The study-group assignments were blinded to the statistician, members of the independent clinical event committee, steering committee, clinical research organization (Research Institute for Production Development, Kyoto, Japan), angiographic core laboratory (Cardiocore, Tokyo, Japan), and the sponsor (Abbot Vascular; List B in the Data Supplement). The principal investigator and the steering committee members designed the study in collaboration with the sponsor. The baseline and follow-up data were collected by the clinical research coordinators from the participating centers, local site management organizations, and the clinical research organization.
Antithrombotic Therapy
Procedural anticoagulation was achieved with unfractionated heparin following the local site protocols. The recommended antiplatelet regimen included aspirin (≥81 mg QD) indefinitely and thienopyridines (75 mg clopidogrel or 200 mg ticlopidine QD) for ≥3 months. The duration of the dual antiplatelet therapy was left to the discretion of each attending physician. The status of antiplatelet therapy was evaluated throughout the follow-up period. 11 Discontinuation of thienopyridines and aspirin was defined to be persistent when withdrawn for >2 months. Discontinuation of dual antiplatelet therapy was defined as persistent discontinuation of either thienopyridines or aspirin.
Primary and Secondary End Points
The primary efficacy end point was any TLR at 1 year, whereas the primary safety end point was a composite of all-cause death or myocardial infarction (MI) at 3 years. The secondary end points included acute device success, duration of the index procedure, clinically driven TLR, target vessel revascularization (TVR), any coronary revascularization, all-cause death, cardiac death, MI, stent thrombosis (ST), hospitalization for heart failure, stroke, bleeding, a device-oriented composite (cardiac death, target-vessel MI, and TLR), a patient-oriented composite (all-cause death, MI, and any repeat coronary revascularization), target-lesion failure (TLF: cardiac death, target-vessel MI, or ischemiadriven TLR), target-vessel failure (TVF: cardiac death, MI, or ischemia-driven TVR), and major adverse cardiac events (MACEs: cardiac death, MI, or ischemia-driven TLR). Bleeding events were adjudicated by the criteria from thrombolysis in myocardial infarction and from Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO). Definitions for the other end points were described previously in detail. 1 The primary end point events were adjudicated by the independent clinical event committee. For the patients with TVR, all angiograms were to be analyzed by the angiographic core laboratory to discriminate TLR from non-TLR TVR.
Statistical Analyses
The trial was a noninferiority trial enrolling 3200 patients, which had 95% power for evaluating noninferiority of EES to SES on the primary efficacy end point at 1 year after the index procedure. 1 The sample size of the trial had 91% power for evaluating noninferiority of EES to SES on the primary safety end point at 3 years with noninferiority margin of 4.3% for the assumed event rate of 12.2%.
Categorical variables were presented as counts and percentages and were compared using the χ 2 test or Fisher exact test. Continuous variables were expressed as mean±SD or median with interquartile range. Continuous variables were compared using the Student t test or Wilcoxon rank-sum test based on their distributions. Clinical outcomes were analyzed according to the intention-to-treat principle.
WHAT IS KNOWN
• Multiple previous head-to-head randomized trials comparing everolimus-eluting stent (EES) with sirolimus-eluting stent (SES) have demonstrated comparable results with respect to the efficacy and safety outcomes ≤1 year.
• However, long-term clinical outcomes of EES compared with SES have not been fully evaluated yet, especially whether EES implantation could positively affect late adverse events reported after SES implantation occurring >1 year.
WHAT THE STUDY ADDS
• The efficacy (target-lesion revascularization) and safety (all-cause death/myocardial infarction) outcomes after EES implantation remained comparable with those after SES implantation through 3-year follow-up.
• The benefits of EES use over SES use for late adverse events, such as very late stent thrombosis and late target-lesion revascularization, could not be observed clearly with 3-year follow-up.
• However, improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the significantly lower cumulative incidences of target-lesion failure, which has been the most widely used primary end point in the stentversus-stent trials.
Each end point was assessed by the Kaplan-Meier method and was compared by the log-rank test. Treatment effect was estimated by the Cox proportional hazard models and was expressed by hazard ratio with 95% confidence interval. Clinical follow-up at 3 years was regarded to be achieved with an allowance of 2 months (≥34 months of follow-up). We conducted the lesion-based analyses as sensitivity analyses with the assumption that multiple lesions within the same patient were considered independent of each other clinically. As a subgroup analysis, treatment effect of EES relative to SES was evaluated in several prespecified subgroups including those patients with diabetes mellitus, insulin-treated diabetes mellitus, advanced age, hemodialysis, and multivessel PCI. Clinical outcomes between 1 and 3 years were evaluated using the landmark analysis method, in which we set the 1-year landmark point.
All 
Results
Patient Characteristics and Revascularization Procedures
Clinical Outcomes Through 3 Years
At 3 years, clinical follow-up was completed in 3102 patients (97.1%; Figure 1 ). The cumulative incidence of persistent discontinuation of dual antiplatelet therapy was not significantly different between the EES and SES groups (12.5% versus 12.3% at 1 year and 34.7% versus 35.0% at 3 years; P=0.81; Figure 2 ). Almost two thirds of patients in both groups had continued dual antiplatelet therapy even at 3 years after stent implantation. At 3 years, the cumulative incidence of all-cause death/ MI (primary safety end point) was 10.1% (159 patients with ≥1 event) in the EES group and 11.5% (182 patients with ≥1 event) in the SES group (Table 2; Figure 3 ). The upper 95% confidence interval of the difference in the rate of all-cause death/MI between the EES and SES groups (−1.4% [95% confidence interval, −4.6% to 1.8%]) was smaller than the prespecified noninferiority margin of 4.3%, demonstrating noninferiority of EES to SES (noninferiority P<0.001) in terms of the primary safety end point. However, testing for superiority was not statistically significant (P=0.19). Cumulative incidence of definite ST was low and was not different between the 2 groups (0.5% versus 0.6%; P=0.81; Table 2 ).
About the efficacy end point of TLR, any TLR occurred in 102 patients (6.6%) in the EES group and in 122 patients (7.9%) in the SES group without statistically significant difference (P=0.16; Table 2 ; Figure 3 ). Cumulative incidences of TVR and clinically driven TLR were also not significantly different between the EES and SES groups ( Table 2 ). The angiographic core laboratory evaluated the angiograms at the time of events in 211 of 224 TLR events (94%) and in 304 of 333 TVR events (91%). During the 3-year period, follow-up angiography was performed in 2365 of 3196 patients (76%).
The EES group as compared with the SES group had significantly lower cumulative incidences of TLF (8.8% versus 11.4%; P=0.01), which has been most widely adopted as the primary end point in the stent-versus-stent trials. The cumulative 3-year incidences of several other prespecified secondary end points, including TVF, a device-oriented composite, and MACE were also significantly lower in the EES group than in the SES group (Table 2; Figure 4 ).
Lesion-Based Analyses
In the 1888 lesions exclusively treated with EES and 1858 lesions with SES, the cumulative incidence of lesion-based TLR was not different between the EES and SES groups (5.5% versus 6.7%; P=0.12). However, lesion-based clinically driven TLR was significantly lower in the EES group than that in the SES group (3.9% versus 5.3%; P=0.048).
Late Adverse Events Between 1 and 3 Years
Between 1 and 3 years, the cumulative incidences of both definite VLST and late TLR were not significantly different between the EES group and the SES group (0.2% versus 0.2%; P=0.99 and 2.2% versus 2.9%; P=0.21, respectively; Table 3 ; Figure 5 ). However, there was a statistically insignificant trend favoring EES with respect to the several secondary end points, such as TLF, TVF, a device-oriented composite, and MACE (Table 3) .
Subgroup Analysis
For the subgroup analysis, the cumulative incidence of TLR in patients with insulin-treated diabetes mellitus was significantly lower in the EES group than in the SES group (9.2% versus 16.1%; P=0.045), although there was no interaction between the types of stents and insulin-treated diabetes mellitus (interaction P=0.15; Figure 6 ). There was no significant difference in the cumulative incidences of TLR between the EES and SES groups across any other prespecified subgroups ( Figure 6 ).
Discussion
The main findings of the current study were the following: (1) the efficacy (TLR) and safety (all-cause death/MI) outcomes after EES implantation remained comparable with those after SES implantation through 3-year follow-up; (2) the benefits of EES use over SES use for late adverse events, such as VLST and late TLR, could not be clearly observed with 3-year follow-up; (3) however, EES use as compared with SES use was associated with significantly lower cumulative incidences of several prespecified secondary end points, including TLF, TVF, a device-oriented composite, and MACE.
Multiple previous head-to-head randomized trials that compared EES with SES have demonstrated comparable results with respect to the efficacy and safety outcomes ≤1 year. 1-3 However, late adverse events, such as late TLR and VLST, that occurred >1 year after stent implantation were the major limitations of SES and were reported to be a persistent risk for at least up to 5 years after implantation. 12 13 Furthermore, recent reports from observational studies and meta-analyses suggested that the use of EES rather than SES (another first-generation DES) reduces the risk of VLST and repeat revascularization. [4] [5] [6] [7] 14, 15 However, these results should be interpreted carefully because the results came from observational studies using historical control or from meta-analyses that incorporate indirect comparison or include limited data >1 year. Indeed, recent pathological study comparing EES with SES and paclitaxel-eluting stent reported a similar frequency of neoatherosclerosis and fracture-related adverse events between EES and first-generation DES, despite fewer uncovered struts and less inflammation with EES, indicating that careful long-term follow-up remains important even after EES implantation. 16 Head-to-head randomized trials comparing EES with SES reporting clinical outcomes >1 year after implantation were currently limited. 2, 8, 9 The Intracoronary Stenting and Angiographic Results (ISAR)-Test IV study reported no significant difference in the cumulative incidence of definite/probable ST between the EES and SES groups through 3 years (1.4% versus 1.9%; P=0.51) as well as VLST between 1 and 3 years (0% versus 0.3%; P=0.85). 2 The Basel Stent Kosten-Effektivitäts Trial-Prospective Validation Examination (BASKET-PROVE) study also demonstrated the similar incidence of definite ST between the EES and SES groups at 2 years (0.3% versus 0.4%; P=0.85). 9 However, the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT Out IV) study reported significantly lower cumulative 2-year incidence of definite ST in the EES group as compared with that in the SES group (0.2% versus 0.9%; P=0.02). 8 In the current study, there was no significant difference in the cumulative 3-year incidence of definite ST between the 2 types of stents. Inconsistency on the effect of EES relative to SES on ST among these large randomized trials could largely be explained by the low event rates of ST, where the possibility of play of chance becomes greater. In the current study, the annual rate of VLST in the SES group (0.1%/y) was remarkably lower than that reported in the realworld SES registry in Japan (0.26%/y). 12 The different rates of VLST could be explained by the different complexities of the patients and lesions enrolled either in the randomized controlled trial or in the real-world registry. Also, the high rate of dual antiplatelet therapy administration >1 year might be related to the low VLST rate in the SES group observed in this study. Considering the low annual event rate for ST, a larger scale and longer term follow-up study would be necessary to evaluate the effect of EES use relative to SES use on the incidence of ST. In the current study, intravascular ultrasound was used in a large proportion of patients at the time of index stent implantation, and dual antiplatelet therapy was maintained in almost two thirds of patients at 3 years. However, it is not known how much impact did these features in the current study had on the low incidence of definite ST.
The current study also showed no significant difference between EES and SES in terms of late TLR, which has been reported as another important late adverse event after SES implantation. In all the head-to-head randomized trials comparing EES with SES reporting clinical outcomes >1 year after implantation, cumulative incidence of TLR was not significantly different between the EES and SES groups (12.8% versus 15.5%, P=0.15 at 3 years in the ISAR-Test IV study; 2.9% versus 3.5%, P=0.33 at 2 years in the SORT Out IV study; 3.7% versus 4.3%, P=0.85 at 2 years in the BASKET-PROVE study; and 6.6% versus 7.9%, P=0.16 at 3 years in the current study, respectively). 2, 8, 9 Relatively large variations in the cumulative incidence of TLR across these 4 studies including ours might be related to the differences in the risk profiles of patients enrolled and the prevalence of angiographic follow-up. Although the individual trials did not have sufficient power to demonstrate significant difference in the cumulative incidence of TLR out to 2 to 3 years, it was noteworthy that EES use as compared with SES use consistently resulted in 12% to 20% relative risk reduction for TLR. Considering lowrisk nature of the present population and limited duration of follow-up, we could not exclude the possibility of superior long-term antirestenotic efficacy of EES. Therefore, a longer term follow-up study would be necessary to evaluate the clinical benefit of EES use over SES use, especially for late adverse events, such as VLST and late TLR.
Despite lack of significant differences in the cumulative incidences of the primary efficacy and safety end points, it was noteworthy to observe significant differences in the cumulative incidence of several prespecified secondary composite end points with only 3-year follow-up. Improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the significantly lower cumulative incidences of TLF, which has been most widely adopted as the primary end point in the stent-versus-stent trials.
Study Limitations
There are several important limitations in the current study although it was the largest scale trial comparing EES with SES with 3-year follow-up. First, follow-up duration of 3 years was not long enough to evaluate the late adverse events, such as late TLR and VLST. Second, the sample size in the current study was still too small to evaluate the low-frequency events, such as VLST. Third, in this physician-directed study, patients were not fully monitored, and collection of clinical events was based on self-reporting by the site investigators. We could not exclude the possibility of under-reporting of clinical events, definite ST in particular. However, annual rates of other clinical events, such as death, and MI seemed not to be lower than those reported in the Cypher Japan Post-Marketing Surveillance (J-PMS) study, which was a fully monitored company-directed postmarket surveillance registry of 2000 patients undergoing SES implantation in Japan. 17 Furthermore, the presence or absence of thrombus at the stented site was analyzed carefully by the angiographic core laboratory in patients with TVR. Also, adjudication of events was conducted carefully by the independent clinical event committee in patients who died or had MI in an attempt to exclude the possibility of unreported ST. Therefore, it would be unlikely for the low rate of ST event to be attributable to significant under-reporting of events. Fourth, the open-label trial design might have influenced the decisions of the attending physicians on the management of antiplatelet therapy as well as the conduct of TLR. Fifth, patient demographics, practice patterns, including the long duration of dual antiplatelet therapy as well as high rate of follow-up angiography, and low event rates for MI and ST in patients undergoing PCI in Japan may be different from those outside Japan. Extrapolating the current study results to populations outside Japan should be done with caution. Finally, although we found significantly lower cumulative incidences of TLF, TVF, a device-oriented composite, and MACE in the EES group than in the SES group, we should interpret these data carefully because these kinds of composite end points included outcomes not related to stent performance itself.
Conclusions
The efficacy and safety outcomes for this trial after EES implantation remained comparable with those after SES implantation through 3-year follow-up. However, improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the significantly lower cumulative incidences of TLF, which has been the most widely used primary end point in the stent-versus-stent trials.
